Vera Therapeutics, Inc. (VERA) shareholders
Close on Nov 16, 2026Market cap $1.94BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC Joint filing with Behzad Aghazadeh (8.90%) | 5,610,000 | 8.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 5,340,522 | 7.40% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick G. Enright Joint filing with Juliet Tammenoms Bakker (8.30%), Longitude Capital Partners IV, LLC (5.50%) and 1 more | 5,184,062 | 8.40% | 13D (active) amendment | Oct 31, 2024 |
| T. Rowe Price Associates, Inc. | 4,573,684 | 6.40% | 13G (passive) amendment | Mar 31, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.50%), David Kroin (5.50%) | 3,921,362 | 5.50% | 13G (passive) | Mar 4, 2026 |
| Kynam Capital Management, LP Joint filing with Kynam Capital Management GP, LLC (5.37%), Yue Tang (5.37%) | 3,426,887 | 5.37% | 13G (passive) | Jun 30, 2025 |
| Deerfield Partners, L.P. Joint filing with Deerfield Mgmt, L.P. (5.25%), Deerfield Management Company, L.P. (5.25%) and 1 more | 3,348,117 | 5.25% | 13G (passive) | Jun 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VERA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,747,760 | 7.98% | $246.64M | +659,658 | 0.00% |
| Avoro Capital Advisors LLC | 5,723,888 | 7.94% | $245.61M | −165,000 | 2.21% |
| State Street Corp | 4,148,786 | 5.76% | $178.02M | +785,148 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 4,012,936 | 5.57% | $172.20M | −561,094 | 0.02% |
| Deep Track Capital, LP | 4,000,000 | 5.55% | $171.64M | −106,067 | 2.50% |
| Deerfield Management Company, L.P. (Series C) | 3,916,400 | 5.43% | $168.05M | +194,300 | 1.75% |
| Kynam Capital Management, LP | 2,890,059 | 4.01% | $124.01M | −508,165 | 6.85% |
| Morgan Stanley | 2,799,459 | 3.88% | $120.12M | +2,430,699 | 0.01% |
| Sofinnova Investments, Inc. | 2,793,987 | 3.88% | $119.89M | – | 6.20% |
| FMR LLC | 2,774,070 | 3.85% | $119.04M | +97,648 | 0.01% |
| Vanguard Capital Management LLC | 2,755,413 | 3.82% | $118.23M | +71,806 | 0.00% |
| Eversept Partners, LP | 2,212,770 | 3.07% | $94.95M | +39,484 | 4.93% |
| Logos Global Management LP | 2,200,000 | 3.05% | $94.40M | New | 4.06% |
| Integral Health Asset Management, LLC | 1,750,000 | 2.43% | $75.09M | +150,000 | 2.97% |
| Bellevue Group AG | 1,710,808 | 2.37% | $73.41M | +37 | 1.54% |
| Geode Capital Management, LLC | 1,692,442 | 2.35% | $72.64M | +122,365 | 0.00% |
| Alliancebernstein L.P. | 1,591,043 | 2.21% | $64.01M | +276,801 | 0.02% |
| Goldman Sachs Group Inc | 1,380,835 | 1.92% | $59.25M | +246,866 | 0.01% |
| Frontier Capital Management Co LLC | 1,295,405 | 1.80% | $55.59M | +743,912 | 0.52% |
| Pictet Asset Management Holding SA | 1,249,414 | 1.73% | $53.63M | +197,831 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 219 | 78M | 100.0% | 30 / 100 | 66 / 37 | 13M | 8M |
| Q1 2026 | 229 | 72M | 100.0% | 47 / 94 | 65 / 29 | 11M | 10M |
| Q4 2025 | 214 | 74M | 100.0% | 62 / 79 | 59 / 18 | 18M | 9M |
| Q3 2025 | 175 | 65M | 90.4% | 35 / 66 | 49 / 32 | 12M | 11M |
| Q2 2025 | 172 | 64M | 88.7% | 34 / 71 | 48 / 40 | 15M | 15M |
| Q1 2025 | 179 | 64M | 88.3% | 34 / 73 | 46 / 32 | 10M | 9M |
| Q4 2024 | 178 | 63M | 87.3% | 32 / 97 | 36 / 23 | 13M | 4M |
| Q3 2024 | 173 | 54M | 74.4% | 27 / 67 | 53 / 24 | 10M | 7M |
| Q2 2024 | 171 | 55M | 75.8% | 38 / 68 | 54 / 23 | 10M | 10M |
| Q1 2024 | 159 | 55M | 76.2% | 72 / 52 | 31 / 8 | 24M | 11M |
| Q4 2023 | 95 | 43M | 59.5% | 22 / 33 | 21 / 10 | 8M | 4M |
| Q3 2023 | 84 | 39M | 54.5% | 17 / 38 | 15 / 8 | 6M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
205 funds held VERA in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VERA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,650,187 | 3.68% | $113.72M | 1.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,933,728 | 2.68% | $82.98M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,664,738 | 2.31% | $71.43M | 0.09% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,014,457 | 1.41% | $43.53M | 0.30% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 872,624 | 1.21% | $31.00M | 0.03% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 784,306 | 1.09% | $33.65M | 0.28% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 759,558 | 1.05% | $32.59M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 698,793 | 0.97% | $22.43M | 0.07% | Jul 31, 2026 |
| Small Cap Growth Fund | 658,959 | 0.91% | $21.15M | 0.38% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 647,781 | 0.90% | $27.80M | 0.28% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 590,030 | 0.82% | $25.32M | 0.16% | Jun 30, 2026 |
| iShares Biotechnology ETF | 414,491 | 0.58% | $17.79M | 0.20% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 376,729 | 0.52% | $16.17M | 0.52% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 333,353 | 0.46% | $11.84M | 0.03% | May 31, 2026 |
| Ab Discovery Growth Fund, Inc. | 323,006 | 0.45% | $13.86M | 0.48% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marshall Fordyce | PRESIDENT AND CEO, Director | 475,774 | 0.66% | Sep 17, 2026 |
| Joseph R. Young | SVP, FINANCE, CHIEF ACCT OFFCR | 80,754 | 0.11% | Sep 14, 2026 |
| Nancy Lee Boman | Chief Regulatory Officer | 44,987 | 0.06% | Aug 5, 2026 |
| Jane Wright-Mitchell | Chief Legal Officer | 42,403 | 0.06% | Mar 25, 2026 |
| Laurence Matthew Skelton | Chief Commercial Officer | 64,218 | 0.09% | Feb 25, 2026 |
| Sean Grant | CHIEF FINANCIAL OFFICER | 119,181 | 0.17% | Feb 25, 2026 |
| David Lee Johnson | Chief Operating Officer | 45,727 | 0.06% | Feb 25, 2026 |
| William D. Turner | Chief Regulatory Officer | 45,313 | 0.06% | Feb 25, 2026 |
| Robert Brenner | Chief Medical Officer | 50,947 | 0.07% | Feb 25, 2026 |
| Jason S. Carter | Chief Legal Officer | 49,136 | 0.07% | Nov 25, 2025 |
| Scott W. Morrison | Director | – | – | May 26, 2026 |
| Michael Morrissey | Director | 0 | – | May 26, 2026 |
| Andrew Cheng | Director | 17,488 | 0.02% | May 26, 2026 |
| James R. Meyers | Director | – | – | May 26, 2026 |
| Kimball Hall | Director | 0 | – | May 26, 2026 |
| Christy J. Oliger | Director | 2,987 | 0.00% | May 26, 2026 |
| Beth C. Seidenberg | Director | 135,565 | 0.19% | May 26, 2026 |
| Patrick G. Enright | Director | 3,602,475 | 5.00% | May 26, 2026 |
| Christopher Hite | Director | – | – | Mar 9, 2026 |
| Maha Katabi | Director | 5,975,429 | 8.29% | May 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 15, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −18,500 | $37.00 | $684.50K | 235,244 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Sep 11, 2026 | Option exercise | +5,000 | $3.94 | $19.70K | 80,754 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 2, 2026 | Sale(10b5-1 plan) | −18,500 | $35.12 | $649.72K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Sep 2, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Nancy Lee Boman Chief Regulatory Officer | Aug 3, 2026 | Award | +44,987 | – | – | 44,987 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −32,550 | $42.07 | $1.37M | 247,944 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −10,500 | $42.86 | $450.03K | 237,444 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −2,200 | $43.59 | $95.90K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −1,000 | $40.78 | $40.78K | 280,494 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Option exercise | +46,250 | $2.90 | $134.13K | 281,494 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −10,500 | $42.86 | $450.03K | 154,194 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −1,000 | $40.78 | $40.78K | 197,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −32,550 | $42.07 | $1.37M | 164,694 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −2,200 | $43.59 | $95.90K | 151,994 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −18,412 | $37.93 | $698.37K | 235,332 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −88 | $38.43 | $3.38K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −88 | $38.43 | $3.38K | 198,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Jun 23, 2026 | Sale(10b5-1 plan) | −18,412 | $37.93 | $698.37K | 198,332 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −14,219 | $36.64 | $520.98K | 239,525 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −4,281 | $37.09 | $158.78K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Option exercise | +18,500 | $2.90 | $53.65K | 253,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −4,281 | $37.09 | $158.78K | 216,744 |
| Marshall Fordyce PRESIDENT AND CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −14,219 | $36.64 | $520.98K | 221,025 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −7,921 | $44.58 | $353.12K | 236,144 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −900 | $45.51 | $40.96K | 235,244 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −14,130 | $43.66 | $616.92K | 244,065 |
| Jane Wright-Mitchell Chief Legal Officer | Mar 23, 2026 | Award | +42,403 | – | – | 42,403 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Mar 13, 2026 | Option exercise | +10,000 | $3.94 | $39.40K | 75,754 |
| William D. Turner Chief Regulatory Officer | Feb 23, 2026 | Sale | −2,187 | $41.98 | $91.81K | 45,313 |
| Sean Grant CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −4,949 | $41.98 | $207.76K | 114,181 |
| Robert Brenner Chief Medical Officer | Feb 23, 2026 | Sale | −2,151 | $41.98 | $90.30K | 50,947 |
| Laurence Matthew Skelton Chief Commercial Officer | Feb 23, 2026 | Sale | −1,582 | $41.98 | $66.41K | 64,218 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 23, 2026 | Sale | −16,925 | $41.98 | $710.51K | 257,163 |
| David Lee Johnson Chief Operating Officer | Feb 23, 2026 | Sale | −2,579 | $41.98 | $108.27K | 45,727 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Feb 23, 2026 | Sale | −3,117 | $41.98 | $130.85K | 64,722 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Feb 4, 2026 | Award | +10,000 | – | – | 67,839 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 4, 2026 | Award | +68,800 | – | – | 274,088 |
| Sean Grant CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Award | +25,000 | – | – | 119,130 |
| Robert Brenner Chief Medical Officer | Feb 4, 2026 | Award | +25,000 | – | – | 53,098 |
| Laurence Matthew Skelton Chief Commercial Officer | Feb 4, 2026 | Award | +20,000 | – | – | 65,800 |
| William D. Turner Chief Regulatory Officer | Feb 4, 2026 | Award | +25,000 | – | – | 47,500 |
| David Lee Johnson Chief Operating Officer | Feb 4, 2026 | Award | +20,000 | – | – | 48,306 |
| William D. Turner Chief Regulatory Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −10,000 | $50.08 | $500.80K | 22,500 |
| William D. Turner Chief Regulatory Officer | Dec 15, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| Patrick G. Enright Director | Dec 11, 2025 | Buy | +5,882 | $42.50 | $249.99K | 5,882 |
| William D. Turner Chief Regulatory Officer | Dec 8, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| William D. Turner Chief Regulatory Officer | Dec 8, 2025 | Sale(10b5-1 plan) | −10,000 | $45.31 | $453.10K | 22,500 |
| William D. Turner Chief Regulatory Officer | Dec 3, 2025 | Option exercise | +10,000 | $15.53 | $155.30K | 32,500 |
| William D. Turner Chief Regulatory Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −10,000 | $40.00 | $400.00K | 22,500 |
| Jason S. Carter Chief Legal Officer | Nov 21, 2025 | Sale | −3,864 | $27.82 | $107.50K | 49,136 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Nov 13, 2025 | Option exercise | +10,000 | $3.94 | $39.40K | 57,839 |
| Joseph R. Young SVP, FINANCE, CHIEF ACCT OFFCR | Nov 11, 2025 | Sale | −15,000 | $29.06 | $435.90K | 47,839 |
| Patrick G. Enright Director | Jun 24, 2025 | Buy | +13,536 | $22.35 | $302.53K | 1,797,619 |
| Patrick G. Enright Director | Jun 24, 2025 | Buy | +27,071 | $22.35 | $605.04K | 3,596,593 |
| Patrick G. Enright Director | Jun 23, 2025 | Buy | +139,595 | $20.87 | $2.91M | 3,569,522 |
| Patrick G. Enright Director | Jun 23, 2025 | Buy | +69,798 | $20.87 | $1.46M | 1,784,083 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 26, 2025 | Sale(10b5-1 plan) | −1,100 | $28.32 | $31.15K | 204,665 |
| Marshall Fordyce PRESIDENT AND CEO, Director | Feb 26, 2025 | Sale(10b5-1 plan) | −7,975 | $27.55 | $219.71K | 205,765 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vera Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,630 shares on Oct 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marshall Fordyce Director, Officer | Sep 2, 2026 | 64,750 | $2.22M | Sep 2, 2026 | Exercise of Stock Options |
| Marshall Fordyce Director, Officer | Jun 23, 2026 | 74,000 | $2.84M | Jun 23, 2026 | Exercise of Stock Options |
| Marshall Fordyce Director, Officer | May 12, 2026 | 18,500 | $677.29K | May 12, 2026 | Exercise of Stock Options |
| Marshall Fordyce Director, Officer | Apr 14, 2026 | 22,951 | $1.00M | Apr 14, 2026 | Restricted Stock Units |
| Marshall Fordyce Officer | Feb 23, 2026 | 16,600 | $697.78K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| David Lee Johnson Officer | Feb 23, 2026 | 2,900 | $121.90K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Robert Brenner Officer | Feb 23, 2026 | 2,500 | $105.09K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Sean Grant Officer | Feb 23, 2026 | 5,700 | $239.60K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| William D. Turner Officer | Feb 23, 2026 | 2,600 | $109.29K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| Laurence Matthew Skelton Officer | Feb 23, 2026 | 1,800 | $75.66K | Feb 23, 2026 | Restricted stock vesting under a registered plan |
| William D. Turner Officer | Dec 15, 2025 | 10,000 | $498.00K | Dec 15, 2025 | Exercise of Stock Options |
| William D. Turner Officer | Dec 8, 2025 | 10,000 | $449.00K | Dec 8, 2025 | Exercise of Stock Options |
| William D. Turner Officer | Dec 3, 2025 | 10,000 | $372.50K | Dec 3, 2025 | Exercise of Stock Options |
| Jason S. Carter Officer | Nov 24, 2025 | 3,864 | $107.69K | Nov 21, 2025 | Restricted Stock Unit Award |
| Marshall Fordyce Director, Officer | Feb 26, 2025 | 9,075 | $245.93K | Feb 26, 2025 | Restricted Stock Units |
See a number that looks wrong?